First - line, non - cryopreserved autologous stem cell transplant for poor - risk germ - cell tumors: Experience in a developing country

PURPOSE: The current first - line treatment for non - seminomatous germ cell tumor (NSGCT) consists of four cycles of cisplatin, etoposide, and bleomycin (BEP), which results in 5 - year overall survival < 60% in patients with poor - risk features. Autologous hematopoietic stem cell transplantati...

Descripción completa

Detalles Bibliográficos
Autores principales: Leon-Rodriguez, Eucario, Rivera-Franco, Monica M., Lacayo-Leñero, Dennis, Campos-Castro, Andrea, Meneses-Medina, Monica I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Urologia 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442144/
https://www.ncbi.nlm.nih.gov/pubmed/30325602
http://dx.doi.org/10.1590/S1677-5538.IBJU.2017.0562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442144/
https://www.ncbi.nlm.nih.gov/pubmed/30325602
http://dx.doi.org/10.1590/S1677-5538.IBJU.2017.0562

Ejemplares similares